126 related articles for article (PubMed ID: 26829656)
1. Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
Park D; Ha IJ; Park SY; Choi M; Lim SL; Kim SH; Lee JH; Ahn KS; Yun M; Lee SG
J Nat Prod; 2016 Feb; 79(2):317-23. PubMed ID: 26829656
[TBL] [Abstract][Full Text] [Related]
2. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
4. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin.
Lee DH; Lee CS; Kim DW; Ae JE; Lee TH
Anticancer Drugs; 2014 Jan; 25(1):44-52. PubMed ID: 24045365
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
6. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
8. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Yoshida T; Shiraishi T; Horinaka M; Nakata S; Yasuda T; Goda AE; Wakada M; Mizutani Y; Miki T; Nishikawa A; Sakai T
Cancer Sci; 2007 Sep; 98(9):1417-23. PubMed ID: 17645780
[TBL] [Abstract][Full Text] [Related]
9. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
[TBL] [Abstract][Full Text] [Related]
10. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
11. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
13. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand.
Nagane M; Cavenee WK; Shiokawa Y
J Neurosurg; 2007 Mar; 106(3):407-16. PubMed ID: 17367063
[TBL] [Abstract][Full Text] [Related]
16. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
17. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
19. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
20. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
